Estrella Immunopharma Stock Volume Indicators Chaikin AD Line
| ESLA Stock | 1.26 0.01 0.80% |
| Symbol |
Indicator |
This analysis covers sixty-one data points across the selected time horizon. The Accumulation/Distribution line was developed by Marc Chaikin. It is interpreted by looking at a divergence in the direction of the indicator relative to Estrella Immunopharma price. If the Accumulation/Distribution Line is trending upward it indicates that the price may follow. If the Accumulation/Distribution Line becomes flat while Estrella Immunopharma price is still rising (or falling) then it signals a flattening of the price values.
Estrella Immunopharma Technical Analysis Modules
Most technical analysis of Estrella Immunopharma help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Estrella from various momentum indicators to cycle indicators. When you analyze Estrella charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Estrella Immunopharma is a Stock instrument traded in United States. This overview emphasizes how Estrella Immunopharma compares to peers on valuation quality and operating consistency. Current metrics include P/B of 4.13. Estrella Immunopharma has a market cap of 81.54 M, ROE of -2.68%.
Methodology
Unless otherwise specified, financial data for Estrella Immunopharma is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Estrella (USA Stocks:ESLA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Estrella Immunopharma may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Estrella Immunopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Estrella Immunopharma's short interest history, or implied volatility extrapolated from Estrella Immunopharma options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Driverless Cars Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Investor Favorites Invested few shares | |
 | FinTech Invested over 20 shares | |
 | Artificial Intelligence Invested few shares | |
 | ESG Investing Invested few shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Momentum Invested over 40 shares | |
 | Cash Cows Invested few shares | |
More Resources for Estrella Stock Analysis
Understanding Estrella Immunopharma typically begins with financial statements and long-term trend review. Estrella Immunopharma's financial ratios translate raw accounting data into comparable profitability and efficiency signals. Selected reports below provide context for Estrella Stock:Estrella Immunopharma has a market cap of 81.54 M, ROE of -2.68%. Review Investing Opportunities for broader portfolio context. This suggests a position in Estrella Immunopharma within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Our How to Invest in Estrella Immunopharma guide provides practical guidance on trading Estrella Stock.Estrella Immunopharma currently shows ROE of -2.68%, market cap of 81.54 Million. Estrella Immunopharma analysis should be paired with portfolio risk and diversification tools before adjusting allocations. A thorough Estrella Immunopharma review pairs this page with the quantitative and comparative resources listed below. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Understanding Estrella Immunopharma includes distinguishing between market value and book value, where book value reflects Estrella's accounting equity. Estrella Immunopharma's market capitalization is 81.54 M. At P/B 4.13, Estrella Immunopharma trades at a significant premium to book value. Enterprise value stands at 51.34 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Estrella Immunopharma's intrinsic value and market price are different measures derived from different inputs. For Estrella Immunopharma, key inputs include a P/B ratio of 4.13, and ROE of -2.68%. The quoted Estrella Immunopharma price is the exchange level where supply meets demand.